Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting

Chaoyu Wang; Yao Liu

doi:10.1186/s13045-023-01420-w

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting

J Hematol Oncol. 2023 Mar 10;16(1):20. doi: 10.1186/s13045-023-01420-w.

Authors

Chaoyu Wang¹, Yao Liu²

Affiliations

¹ Department of Hematology, Chongqing University Cancer Hospital, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing, 400030, China.
² Department of Hematology, Chongqing University Cancer Hospital, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing, 400030, China. liuyao77@cqu.edu.cn.

Abstract

Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3 T-cell-engaging, bispecific antibody capable of recruiting T cells to tumor cells. We have summarized several of the latest reports on glofitamab use in B cell lymphoma therapy from the 2022 ASH Annual Meeting (ASH2022).

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific* / pharmacology
Antibodies, Bispecific* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / therapy
Neoplasm Recurrence, Local / drug therapy
Rituximab / therapeutic use

Substances

glofitamab
Antibodies, Bispecific
Rituximab